APC2 and CYP1B1 methylation changes in the bone marrow of acute myeloid leukemia patients during chemotherapy

Xia,Yongming; Hong,Qingxiao; Chen,Xiaoying; Ye,Huadan; Fang,Lili; Zhou,Annan; Gao,Yuting; Jiang,Danjie; Duan,Shiwei

doi:10.3892/etm.2016.3719

November-2016 Volume 12 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

November-2016 Volume 12 Issue 5

Full Size Image

Article

APC2 and CYP1B1 methylation changes in the bone marrow of acute myeloid leukemia patients during chemotherapy

Authors:
- Yongming Xia
- Qingxiao Hong
- Xiaoying Chen
- Huadan Ye
- Lili Fang
- Annan Zhou
- Yuting Gao
- Danjie Jiang
- Shiwei Duan
View Affiliations / Copyright

Affiliations: Department of Hematology, Yuyao People's Hospital, Ningbo University Yangming Affiliated Hospital, Yuyao, Zhejiang 315400, P.R. China, Zhejiang Provincial Key Laboratory of Pathophysiology, School of Medicine, Ningbo University, Ningbo, Zhejiang 315211, P.R. China
Pages: 3047-3052
|
Published online on: September 20, 2016

https://doi.org/10.3892/etm.2016.3719
Expand metrics +

Abstract

Aberrant promoter DNA methylation is a major mechanism of leukemogenesis in hematologic malignancies, including acute myeloid leukemia (AML). However, the association between promoter methylation with chemotherapeutic outcomes remains unknown. In the present study, bone marrow samples were collected prior to and following chemotherapy in 30 AML patients. Methylation‑specific polymerase chain reaction technology was used to examine the promoter methylation status of adenomatous polyposis col 2 (APC2) and cytochrome P450 family 1 subfamily B polypeptide 1 (CYP1B1). The results revealed no change in the methylation status of the APC2 promoter in patients following various chemotherapy regimens. However, the methylation status of the CYP1B1 promoter changed in response to 6 different chemotherapy regimens. AML patients of the M3 subtype displayed an induction of the CYP1B1 promoter methylation levels more frequently (57.1%) than patients affected by the other subtypes (M1: 33.3%; M2: 12.5%; M4: 16.7%; M5: 0% and M6: 0%). In addition, a higher frequency of male patients (4/13) exhibited modulation of the CYP1B1 promoter methylation status compared with female patients (3/17). Furthermore, of five AML patients with a poor prognosis, two exhibited changes leading to CYP1B1 hypomethylation and two leading to CYP1B1 hypermethylation. By contrast, three other patients exhibited hypermethylation changes along with remission. This may be explained by the different chemotherapy regimens used to treat these patients or by other unknown factors. The present study revealed that CYP1B1 promoter methylation was induced during chemotherapy, whereas the APC2 promoter remained hemimethylated. Furthermore, the changes in CYP1B1 methylation were dependent on the AML subtypes and the gender of the patients.

View Figures

View References

1	Boultwood J and Wainscoat JS: Gene silencing by DNA methylation in haematological malignancies. Br J Haematol. 138:3–11. 2007. View Article : Google Scholar : PubMed/NCBI
2	Powers HR, Bachar M, Savage N, Toscano M and Dainer PM: Azacitidine as salvage therapy for acute myeloid leukemia in a severely ill patient. Hematol Rep. 6:55162014. View Article : Google Scholar : PubMed/NCBI
3	Galm O, Herman JG and Baylin SB: The fundamental role of epigenetics in hematopoietic malignancies. Blood Rev. 20:1–13. 2006. View Article : Google Scholar : PubMed/NCBI
4	Rowe JM: The increasing genomic complexity of acute myeloid leukemia. Best Pract Res Clin Haematol. 27:209–213. 2014. View Article : Google Scholar : PubMed/NCBI
5	Sierra J, Yoshida T, Joazeiro CA and Jones KA: The APC tumor suppressor counteracts beta-catenin activation and H3K4 methylation at Wnt target genes. Genes Dev. 20:586–600. 2006. View Article : Google Scholar : PubMed/NCBI
6	Griffiths EA, Gore SD, Hooker C, McDevitt MA, Karp JE, Smith BD, Mohammad HP, Ye Y, Herman JG and Carraway HE: Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation. Leuk Lymphoma. 51:1711–1719. 2010. View Article : Google Scholar : PubMed/NCBI
7	Faiq MA, Ali M, Dada T, Dada R and Saluja D: A novel methodology for enhanced and consistent heterologous expression of unmodified human cytochrome P450 1B1 (CYP1B1). PLoS One. 9:e1104732014. View Article : Google Scholar : PubMed/NCBI
8	Nagai F, Hiyoshi Y, Sugimachi K and Tamura HO: Cytochrome P450 (CYP) expression in human myeloblastic and lymphoid cell lines. Biol Pharm Bull. 25:383–385. 2002. View Article : Google Scholar : PubMed/NCBI
9	DiNardo CD, Gharibyan V, Yang H, Wei Y, Pierce S, Kantarjian HM, Garcia-Manero G and Rytting M: Impact of aberrant DNA methylation patterns including CYP1B1 methylation in adolescents and young adults with acute lymphocytic leukemia. Am J Hematol. 88:784–789. 2013. View Article : Google Scholar : PubMed/NCBI
10	Fasan A, Alpermann T, Haferlach C, Grossmann V, Roller A, Kohlmann A, Eder C, Kern W, Haferlach T and Schnittger S: Frequency and prognostic impact of CEBPA proximal, distal and core promoter methylation in normal karyotype AML: A study on 623 cases. PLoS One. 8:e543652013. View Article : Google Scholar : PubMed/NCBI
11	Chen C, Wang L, Liao Q, Huang Y, Ye H, Chen F, Xu L, Ye M and Duan S: Hypermethylation of EDNRB promoter contributes to the risk of colorectal cancer. Diagn Pathol. 8:1992013. View Article : Google Scholar : PubMed/NCBI
12	Mokarram P, Zamani M, Kavousipour S, Naghibalhossaini F, Irajie C, Sarabi M Moradi and Hosseini SV: Different patterns of DNA methylation of the two distinct O6-methylguanine-DNA methyltransferase (O6-MGMT) promoter regions in colorectal cancer. Mol Biol Rep. 40:3851–3857. 2013. View Article : Google Scholar : PubMed/NCBI
13	Zhang L, Shi J, Xu L, Shi B, Hou P and Ji M: Aberrant DNA methylation of drug metabolism and transport genes in nodular goiter. Thyroid Res. 4:152011. View Article : Google Scholar : PubMed/NCBI
14	Habano W, Gamo T, Sugai T, Otsuka K, Wakabayashi G and Ozawa S: CYP1B1, but not CYP1A1, is downregulated by promoter methylation in colorectal cancers. Int J Oncol. 34:1085–1091. 2009. View Article : Google Scholar : PubMed/NCBI
15	Widschwendter M, Siegmund KD, Müller HM, Fiegl H, Marth C, Müller-Holzner E, Jones PA and Laird PW: Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res. 64:3807–3813. 2004. View Article : Google Scholar : PubMed/NCBI
16	Shahab F and Raziq F: Clinical presentations of acute leukemia. J Coll Physicians Surg Pak. 24:472–476. 2014.PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

APC2 and CYP1B1 methylation changes in the bone marrow of acute myeloid leukemia patients during chemotherapy

This article is mentioned in:

Abstract

Figure 1

Figure 2

Related Articles